Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Clovis Oncology says ‍Ariel3 study successfully achieved primary endpoint​

By: Reuters: Company News
* Clovis oncology presents comprehensive dataset from successful phase 3 Ariel3 maintenance treatment trial of Rucaparib in advanced ovarian cancer at ESMO 2017
Related Stocks:
Clovis Oncology Inc
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.